Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers
Lisa H. Butterfield(Merck & Co., Inc., Rahway, NJ, USA (United States)), Mary L. Disis(University of Washington), Hideaki Tahara(Yale University), Thomas-Oliver Kleen(Yale University), Samir N. Khleif(Georgetown University), Graham Pawelec(Health Sciences North), Cedrik M. Britten(Johannes Gutenberg University Mainz), Sjoerd H. van der Burg(Leiden University Medical Center), Sylvia Janetzki(Yale University), Theresa L. Whiteside(UPMC Hillman Cancer Center), Jon M. Wigginton(Bristol-Myers Squibb (United States)), Wenru Song(Pfizer (United States)), Giuseppe Masucci(Karolinska University Hospital), Leif Håkansson(Lund University), A. Karolina Palucka(Jackson Laboratory), Francesco M. Marincola(Center for Translational Molecular Medicine), Bernard A. Fox(Oregon Health & Science University), Anatoli Malyguine(Science Applications International Corporation (United States)), Holden T. Maecker(Stanford University), Licia Rivoltini(Fondazione IRCCS Istituto Nazionale dei Tumori), David F. Stroncek(Yale University), Yutaka Kawakami(National Institutes of Health), Cristina Maccalli(Azienda Ospedaliera Universitaria Policlinico "G. Martino"), Giorgio Trinchieri(National Cancer Institute), Peter P. Lee(City Of Hope National Medical Center), Lupe G. Salazar(Yale University), Madhav V. Dhodapkar(Emory University), Craig L. Slingluff(University of Virginia Health System), Douglas M. Potter(Yale University), Dolores J. Schendel(Medigene (Germany)), Vernon C. Maino(BD Biosciences (United States)), Michele Maio(University of Siena)
Cited by 109
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k